TY - JOUR
T1 - Nonsense-mediated RNA decay is a unique vulnerability of cancer cells harboring sf3b1 or u2af1 mutations
AU - Cheruiyot, Abigael
AU - Li, Shan
AU - Srivatsan, Sridhar Nonavinkere
AU - Ahmed, Tanzir
AU - Chen, Yuhao
AU - Lemacon, Delphine S.
AU - Li, Ying
AU - Yang, Zheng
AU - Wadugu, Brian A.
AU - Warner, Wayne A.
AU - Pruett-Miller, Shondra M.
AU - Obeng, Esther A.
AU - Link, Daniel C.
AU - He, Dalin
AU - Xiao, Fei
AU - Wang, Xiaowei
AU - Bailis, Julie M.
AU - Walter, Matthew J.
AU - You, Zhongsheng
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research Inc.. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMDpromoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes SF3B1 and U2AF1, which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- A nd U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations.
AB - Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMDpromoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes SF3B1 and U2AF1, which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- A nd U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations.
UR - http://www.scopus.com/inward/record.url?scp=85114331969&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-4016
DO - 10.1158/0008-5472.CAN-20-4016
M3 - Article
C2 - 34215620
AN - SCOPUS:85114331969
SN - 0008-5472
VL - 81
SP - 4499
EP - 4513
JO - Cancer research
JF - Cancer research
IS - 17
ER -